Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > News and update

<< Previous

Bullboard Posts

Next >>

Comment by ENEMENEMYNEMOon Jul 09, 2021 9:05am

175 Views

Post# 33520386

RE:RE:RE:RE:News and update

Good points, I became a little distressed when I read that they have only verified 39% of the data and what that meant! Christ do you think Aspire has the assignment key as to who's blinded or not!!

Well either way, as I've said previously, despite Aspires claim the data isn't supportive of a benefit, they for some reason are spending a lot of dollars to retain it and remain a part of the trial!!!

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant